Personalized therapy for acute myeloid leukemia.

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Personalized targeted therapy requires identifying effective drug candidates for individual patients.
• Acute myeloid leukemia (AML) presents challenges in treatment due to evolving resistance and clonal heterogeneity.

Purpose of the Study:

• To evaluate the utility of patient-specific ex vivo drug screening for personalized targeted therapy in AML.
• To characterize mechanisms of drug resistance and clonal evolution during targeted therapy using sequential analysis.

Main Methods:

• Performing ex vivo drug sensitivity and resistance screening tailored to individual patients.
• Iteratively characterizing genomic profiles and drug susceptibility at multiple time points during clinical trials.

Main Results:

• Ex vivo screening can identify rational drug candidates for personalized treatment strategies.
• Sequential genomic and drug susceptibility profiling aids in understanding resistance development and clonal dynamics.

Conclusions:

• Patient-specific ex vivo drug screening is a viable approach for personalized medicine in AML.
• Iterative characterization during clinical trials can uncover novel therapeutic targets and drug combinations for overcoming resistance.